晚期肝细胞癌的全身治疗 - Suppr

Systemic therapy in advanced hepatocellular carcinoma.

作者信息

Ahn Joseph C, Tran Nguyen H, Yang Ju Dong

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.

出版信息

Clin Mol Hepatol. 2023 Apr;29(2):516-519. doi: 10.3350/cmh.2023.0051. Epub 2023 Feb 20.

DOI:10.3350/cmh.2023.0051

PMID:36800697

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10121316/

Abstract

摘要

相似文献

Systemic therapy in advanced hepatocellular carcinoma.

Clin Mol Hepatol. 2023 Apr;29(2):516-519. doi: 10.3350/cmh.2023.0051. Epub 2023 Feb 20.

[New progress in the first-line treatment of advanced hepatocellular carcinoma].

Zhonghua Gan Zang Bing Za Zhi. 2024 Feb 20;32(2):173-179. doi: 10.3760/cma.j.cn501113-20231114-00193.

[Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].

Zhonghua Gan Zang Bing Za Zhi. 2019 Nov 20;27(11):834-837. doi: 10.3760/cma.j.issn.1007-3418.2019.11.005.

[Status and challenges of neoadjuvant immunotherapy for hepatocellular carcinoma].

Zhonghua Wai Ke Za Zhi. 2023 Jan 1;61(1):7-12. doi: 10.3760/cma.j.cn112139-20220819-00361.

Hepatocellular carcinoma in the era of immunotherapy.

Curr Probl Cancer. 2018 Jan-Feb;42(1):40-48. doi: 10.1016/j.currproblcancer.2017.10.007. Epub 2017 Nov 15.

Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.

Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011650. doi: 10.1002/14651858.CD011650.pub2.

Evolution of Systemic Therapy in Advanced Hepatocellular Carcinoma.

Surg Oncol Clin N Am. 2024 Jan;33(1):73-85. doi: 10.1016/j.soc.2023.06.003. Epub 2023 Aug 12.

Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.

Health Technol Assess. 2020 Sep;24(48):1-264. doi: 10.3310/hta24480.

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma.

Front Endocrinol (Lausanne). 2023 Mar 20;14:1150360. doi: 10.3389/fendo.2023.1150360. eCollection 2023.

Combination locoregional and systemic therapies in hepatocellular carcinoma.

Lancet Gastroenterol Hepatol. 2025 Apr;10(4):369-386. doi: 10.1016/S2468-1253(24)00247-4. Epub 2025 Feb 21.

引用本文的文献

Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation.

Hepatology. 2025 Mar 28. doi: 10.1097/HEP.0000000000001328.

An Early Increase in IL-10 and TNF-α Levels Following Atezolizumab Plus Bevacizumab Treatment Predicts Survival in Advanced Hepatocellular Carcinoma Patients: A Prospective Cohort Study.

Cancers (Basel). 2024 Oct 21;16(20):3543. doi: 10.3390/cancers16203543.

CCL5/CCR5/CYP1A1 pathway prompts liver cancer cells to survive in the combination of targeted and immunological therapies.

Cancer Sci. 2024 Nov;115(11):3552-3569. doi: 10.1111/cas.16320. Epub 2024 Aug 25.

Front Immunol. 2024 Jun 11;15:1424752. doi: 10.3389/fimmu.2024.1424752. eCollection 2024.

What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?

Clin Mol Hepatol. 2023 Apr;29(2):332-334. doi: 10.3350/cmh.2023.0080. Epub 2023 Mar 16.

The prime time for management of hepatocellular carcinoma in Hong Kong.

Clin Mol Hepatol. 2023 Apr;29(2):345-348. doi: 10.3350/cmh.2023.0094. Epub 2023 Mar 9.

Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison.

Clin Mol Hepatol. 2023 Apr;29(2):252-262. doi: 10.3350/cmh.2023.0099. Epub 2023 Mar 10.

本文引用的文献

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.

Evolving therapeutic landscape of advanced hepatocellular carcinoma.

Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):203-222. doi: 10.1038/s41575-022-00704-9. Epub 2022 Nov 11.

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.

Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.

Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.

Cardiovasc Intervent Radiol. 2022 Apr;45(4):405-412. doi: 10.1007/s00270-021-03031-9. Epub 2022 Feb 4.

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.

J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.

Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.

Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1025-1035. doi: 10.1016/S2468-1253(21)00305-8. Epub 2021 Oct 23.

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.

J Clin Oncol. 2021 Sep 20;39(27):3002-3011. doi: 10.1200/JCO.21.00163. Epub 2021 Jun 29.

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.

Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15.

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet Gastroenterol Hepatol. 2021 Jul;6(7):559-568. doi: 10.1016/S2468-1253(21)00109-6. Epub 2021 May 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Systemic therapy in advanced hepatocellular carcinoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献